Society of Nuclear Medicine -- 52nd Annual Meeting. Cancer therapeutics, 18-22 June, 2005, Toronto, Canada.
Jago
Charlotte
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. charlotte.jago@thomson.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000503:physiopathology / Q000532:radiotherapy*; D010148:Intractable Pain / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010879:Piperazines; D011725:Pyridines; C448700:epratuzumab; D004815:Epidermal Growth Factor; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide